Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 2090910

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 2090910

Global Viral Capsid Development Market Size, Share, Trends & Growth Analysis Report 2026-2034

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3920
PDF & Excel (10-user License)
USD 4730
PDF & Excel (Corporate User License)
USD 7430

Add to Cart

The global viral capsid development market size is expected to reach USD 823.57 Million in 2034 from USD 334.76 Million in 2025, growing at a CAGR of 10.52 during 2026-2034.This market is experiencing significant growth as gene therapy, vaccine development, and advanced biologics continue transforming modern healthcare. Viral capsids play a crucial role in delivering therapeutic genes and vaccines with high precision, making them essential components in gene editing, cell therapy, and viral vector manufacturing. Increasing investments in biotechnology research, precision medicine, and advanced therapeutic development are driving strong global demand for viral capsid development technologies.

Growing clinical research involving adeno-associated viruses, lentiviral vectors, and other viral delivery platforms is accelerating innovation across the pharmaceutical and biotechnology industries. Technological advancements in capsid engineering, protein modification, vector optimization, and scalable manufacturing processes are improving therapeutic efficiency, targeting accuracy, and production capabilities. Rising prevalence of genetic disorders and increasing demand for innovative treatment approaches are further supporting market growth.

The market is expected to witness substantial expansion as regulatory approvals for gene therapies increase and personalized medicine becomes more widely adopted. Continuous advancements in synthetic biology, artificial intelligence-assisted drug development, and next-generation viral vector engineering will improve therapeutic outcomes and commercial scalability. Expanding research collaborations, increasing healthcare investments, and growing global biotechnology capabilities will continue supporting long-term market growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Adeno-Associated Virus (AAV) Capsids
  • Adenoviral
  • Lentiviral
  • Others

By Application

  • Gene Therapy
  • Vaccine Development
  • Cancer Therapy
  • Others

By End Use

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • CROs & CMOs

COMPANIES PROFILED

  • PackGene Biotech Inc., VectorBuilder, AskBio Inc. (includes Viralgen), Voyager Therapeutics, uniQure N.V., Vigene Biosciences (now part of Charles River Laboratories), Capsigen
Product Code: VMR112118972

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL CAPSID DEVELOPMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Adeno-Associated Virus (AAV) Capsids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Adenoviral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Lentiviral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL CAPSID DEVELOPMENT MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Vaccine Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Cancer Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL CAPSID DEVELOPMENT MARKET: BY END USE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End Use
  • 6.2. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. CROs & CMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL CAPSID DEVELOPMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By End Use
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By End Use
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By End Use
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By End Use
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By End Use
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VIRAL CAPSID DEVELOPMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 PackGene Biotech Inc
    • 9.2.2 VectorBuilder
    • 9.2.3 AskBio Inc. (includes Viralgen)
    • 9.2.4 Voyager Therapeutics
    • 9.2.5 UniQure N.V
    • 9.2.6 Vigene Biosciences (now Part Of Charles River Laboratories)
    • 9.2.7 Capsigen
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!